Nanostructured materials in drug and gene delivery: A review of the state of the art

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 28, Issue 2, 2011, Pages 101-164

  Petkar, Kailash C ^a   Chavhan, Sandip S ^a   Agatonovik Kustrin, Snezana ^b   Sawant, Krutika K ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

Cyclodextrin; Dendrimer; Fullerene; Gold and silica nanoparticle; Nanostructured lipid carrier; Polymeric micelle; Polymeric nanoparticle; Polymersomes; Quantum dots; Solid lipid nanoparticle

Indexed keywords

ALGINIC ACID; ANALGESIC AGENT; ANTIRETROVIRUS AGENT; CARBON NANOTUBE; CHITOSAN; CYCLODEXTRIN; CYCLOSPORIN A; DENDRIMER; DRUG CARRIER; ECONAZOLE; FULLERENE DERIVATIVE; GELATIN; GOLD NANOPARTICLE; HEPATITIS B SURFACE ANTIGEN; MACROGOL; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; POLYACRYLAMIDE; POLYCAPROLACTONE; POLYVINYL ALCOHOL; POVIDONE; QUANTUM DOT; RISPERIDONE; SILICA NANOPARTICLE; SOLID LIPID NANOPARTICLE; TETANUS TOXOID; THEOPHYLLINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHMA; BLOOD BRAIN BARRIER; BREAST CANCER; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; EXTRAPYRAMIDAL SYMPTOM; GENE DELIVERY SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; TUBERCULOSIS;

EID: 79958778180     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v28.i2.10     Document Type: Article

References (312)

1. Chan OH, Schmidt HL, Stilgenbauer LA, Howson W, Horwell DC, Stewart BH. Evaluation of a targeted prodrug strategy to enhance oral absorption of poorly water soluble compounds. Pharm Res. 1998;15:1012-1018.
2. Devane J. Oral drug delivery technology: addressing the solubility/permeability paradigm. Pharm Technol. 1998;22:68-80.
3. Tahan C. Identifying Nanotechnology in Society, In: Marvin Zelkowitz, editor, Advances in Computers -Volume 71. Amsterdam, Elsevier, 2007. P. 251-271.
4. Bawa R. Nano Biotech 2008: Exploring global advances in nanomedicine. Nanomedicine. 2009;5: 5-7.
5. Langer K, Mutschler E, Lambrecht G, Mayer D, Troschau G, Stieneker F, Kreuter J. Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery: Part III: Evaluation as drug delivery system for ophthalmic applications. Int J Pharm. 1997;158:219-231.
6. SGalindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst. 2002;22(5):419-464.
7. Yong-Eun LK, Reddy RG, Bhojani M, Schneider R, Philbert MA, Rehemtulla A, Brian DR, Kopelman R. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Del Rev. 2006;58:1556-1577.
8. Peek LJ, Russell MC, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Del Rev. 2008;60:915-928.
9. Couvreur P, Kante B, Grislain L, Roland M, Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin loaded nanoparticles. J Pharm Sci. 1982;71:790-792.
10. Labhasetwar V, Song C, Levy RJ. Nanoparticles as drug delivery systems. Adv Drug Del Rev. 1997;24:63-85.
11. Magenheim B, Levy MY, Benita S. A new in vitro technique for evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Pharm. 1993;94:115-123.
12. Zur Muhlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery- -drug release and release mechanism. Eur J Pharm Biopharm. 1998;45:149-155.
13. Karanth H, Shenoy VS, Murthy RR. Industrially feasible alternative approaches in the manufacture of solid dispersions: A technical report. AAPS Pharm Sci Tech. 2006;7:1-8.
14. Pillai O, Panchagnula R. Polymers in drug delivery. Curr Opin Chem Biol. 2001;5:447-451.
15. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of PNPs. Int J Pharm. 2006;307:93-102.
16. Peracchia MT, Harnisch S, Pinto-Alphandary H, Gulik A, Dedieu JC, Desmaele D, d'Angelo J, Muller RH, Couvreur P. Visualization of in vitro protein-rejecting properties of PEGylated stealth (R) polycyanoacrylate nanoparticles. Biomaterials. 1999;20:1269-1275.
17. Wei L, Yan Z, Tan Y, Hu K, Jiang X, Fu S. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release. 2005;107:428-448.
18. Clark MA, Jepson MA, Hirst BH, Exploiting M cells for drug and vaccine delivery. Adv Drug Del Rev. 2001;50:81-106.
19. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles, J Control Release. 2005;107:428-448.
20. Jaeghere FD, Allémann E, Doelker E, Cerny GR, Galli B., Steulet AF, Muller I, Schutz H. pH-Dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compound in dogs. AAPS Pharmsci. 2001;3:1-8.
21. Michaelis K, Hoffmann M, Dreis S. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006;317:1246-1253.
22. Lee D, Shirley SA, Lockey RF, Mohapatra SS. Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline. Respir Res. 2006;7:112-122.
23. Qi L, Xu Z, Li Y, Jiang X, Han Y. In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells. World J Gastroenterol. 2005;11:5136-5141.
24. Coester C, Zwiorek K, Kloeckner J, Wagner E. Gelatin nanoparticles as a new and simple gene delivery system. J Pharm Pharmaceut Sci. 2004;7:22-28.
25. Truong-Le VL, Walsh SM, Schweibert E, Mao HQ, Guggino WB, August J, Leong KW. Gene transfer by DNA-gelatin nanospheres. Arch Biochem Biophys. 1999;361:47-56.
26. Balthasar S, Michaelis K, Dinauer N, Von Briesen H, Kreuter J, Langer K. Preparation and characterization of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials. 2005;26:2723-2732.
27. Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, Von Briesen H. Selective targeting of antibody conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials. 2005;26:5898-5906.
28. Azarmi S, Huang Y, Chen H, McQuarrie S, Douglas A, Wilson R, Warren F, Gerald M, Raimar L. Optimisation of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharmaceut Sci. 2006;9:124-132.
29. Lertsutthiwong P, Noomun K, Jongaroonngamsang N, Rojsitthisak P, Nimmannit U. Preparation of alginate nanocapsules containing turmeric oil. Carbohydrate Polymers. 2008;74:209-214.
30. Murakami H, Kobayashia M, Takeuchi H, Kawashima Y. Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm. 1999;187:143-152.
31. Csaba N, Sanchez A, Alonso MJ. PLGA: poloxamer and PLGA: poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Release. 2006;113:164-172.
32. Karine A, Patrick C. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the bloodbrain barrier. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1:463-474.
33. Zhang Y, Zhang Y, Chen J, Zhang B, Pan Y, Ren L, Zhao J, Luo Y, Zhai D, Wang S, Wang J. Polybutylcyanoacrylate nanoparticles as novel vectors in cancer gene therapy. Nanomedicine. 2007;3:144-153.
34. Fresta M, Puqlisi G, Giammona G, Carvellaro G, Micali N, Furneri PM. Pefloxacine mesilate- and ofloxacin-loaded polyethylcyanoacrylate nanoparticles: characterization of the colloidal drug carrier formulation. J Pharm Sci. 1995;84:895-902.
35. Griffith S, Cuellar D, Zulantay I, Gajardo M, Martin GG. Cytotoxicity and trypanocidal activity of nifurtimox encapsulated in ethylcyanoacrylate nanoparticles. Biol Res. 2002;35:39-45.
36. Benoit MA, Baras B., Gillard J. Preparation and characterization of protein-loaded poly(o-caprolactone) microparticles for oral vaccine delivery. Int J Pharm. 1999;184:73-84.
37. Musumecia T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello L, Puglisi G, PLA/ PLGA nanoparticles for sutained release of docetaxel. Int J Pharm. 2006;325:172-179.
38. Bivas-Benita M, Romeijn S, Junginger HE, Borchard G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm. 2004;58:1-6.
39. Aral C, Akbuga J, Preparation and in vitro transfection efficiency of chitosan microspheres containing plasmid DNA: poly(L-lysine) complexes. J Pharm Pharmaceut Sci. 2003;6(3):321-326.
40. Blum JS, Saltzman WM. High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine submicron particles fabricated from PLGA conjugated with poly-L-lysine. J Control Release. 2008;129:66-72.
41. Solaro R. Nanostructured polymeric systems in targeted release of proteic drugs and in tissue engineering. Proceedings of China-EU Forum on Nanosized Technology. Beijing, China: 2002. p 225-244.
42. Bodmeier R, Maincent P. Polymeric dispersions as drug carriers, pharmaceutical dosage form. In: Disperse systems. 3rd ed. New York: Marcel Dekker; 1998. p. 87-127.
43. Vanderhoff JW, EI-Aasser MS., Ugelstad J. Polymer emulsion process. U.S. Patent. 4177177; 1979.
44. Fessi H. Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. U.S. Patent. 5133908; 1999.
45. Bindschaedler C, Gurny R, Doelker E. Process of preparing a powder of water insoluble polymer which can be dispersed in a liquid phase, the resulting powder and utilization thereof. U.S. Patent 4968350; 1990.
46. Vauthier C, Bouchemal B. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009 May;26(5):1025-1058.
47. Torchilin V. Nanoparticulates as drug carriers. 1st ed. New York: London, Imperial College Press; 2006. p. 616.
48. Soppimatha KS, Aminabhavi KS, Kulkarni AS, Rudzinski WE. Biodegradable PNPs as drug delivery devices. J Control Release. 2001;70:1-20.
49. Delie F, Blanco-Prieto MJ, Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules. 2005;10:65-80.
50. Rieux AD, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines:A mechanistic approach. J Control Release. 2006;116:1-27.
51. Koo Y, Reddy GR. Brain cancer diagnosis and therapy with nanoplatform. Adv Drug Del Rev. 2006;58:1556-1577.
52. Vyas TK, Shahiwala A, Amiji MM. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm. 2008;347:93-101.
53. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171-183.
54. Damascelli B, Patelli GP, Lanocita R. A novel intra-arterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol. 2003;181:253-260.
55. Mayer G, Vogela V, Weyermannb J. Oligonucleotide-protamine-albumin nanoparticles: protamine sulfate causes drastic size reduction. J Control Release. 2005;106:181-187.
56. Ravi Kumar MNV, Muzzarelli RAA, Muzzarelli C, Sashiwa H, Domb AJ. Chitosan chemistry and pharmaceutical perspectives. Chem Rev. 2004;104:6017-6084.
57. Waree T. Chitosan nanoparticles: a promising system for drug delivery. Naresuan University Journal. 2003;11(3):51-66.
58. Qi L, Xu Z. In vivo antitumor activity of chitosan nanoparticles. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4243-4245.
59. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine. 2006;1(2):117-128.
60. Shakhweh M, Ponchel G, Fattal E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv. 2004 Nov;1(1):141-163.
61. Ma Z, Lim L-Y. Uptake of chitosan and associated insulin in Caco-2 cell monolayers: a comparison between chitosan molecules and chitosan nanoparticles. Pharm Res. 2003;20:1812-1819.
62. Borges O, Cordeiro-da-Silva A, Romeijn SG, Amidi M, Sousa A, Borchard G, Junginger HE. Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J Control Release. 2006;114:348-358.
63. Grenha A, Grainger CI, Dailey LA, Seijo B, Martin GP, Remuñán-López C, Forbes B. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. Eur J Pharm Sci. 2007 Jun;31(2):73-84.
64. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Vila JL, Alonso MJ. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm. 2004;57:123-131.
65. Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release. 2006;111:107-116.
66. Kommareddy S, Tiwari SB, Amiji MM. Long-circulating polymeric nanovectors for tumour-selective gene delivery. Technol Cancer Res Treat. 2005;4:615-625.
67. Kaul G, Amiji M. Cellular interactions and in vitro DNA transfection studies with poly(ethylene glycol)-modified gelatin nanoparticles. J Pharm Sci. 2005;94:184-198.
68. Kaul G, Amiji M, Long-circulating poly(ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm Res. 2002;19:1061-1067.
69. Won Y, Kim Y. Recombinant human gelatin nanoparticles as a protein drug carrier. J Control Release. 2008;127:154-161.
70. Ahmad Z, Sharma S, Khuller GK. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine. 2007 Sep;3(3):239-243.
71. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs:Alginate and chitosan--a review. J Control Release. 2006;114:1-14.
72. Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine. 2009 Sep;5(3):323-333.
73. Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash A. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009 Dec 9;9:198.
74. Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm. 2008 Feb 12;349(1-2):249-255.
75. Chang J, Jallouli Y, Kroubi M, Yuan X, Feng W, Kang C, Pu P, Betbeder D. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm. 2009 Sep 11;379(2):285-92.
76. Italia JL, Bhatt DK, Bhardwaj V, Tikoo K, Ravi Kumar MNV. PLGA nanoparticles for oral delivery of cyclosporine:Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J Control Release. 2007;119:197-206.
77. Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev. 2009 Feb 27;61(2):140-57.
78. Rytting E, Nguyen J, Wang X, Kissel T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv. 2008;5(6):629-39.
79. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release. 2009;136:2-13.
80. Wendorf J, Singh M, Chesko J, Kazzaz J, Soewanan E, Ugozzoli M, O'Hagan D. A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci. 2006 Dec;95(12):2738-2750.
81. Gupta PN, Khatri K, Goyal AK, Mishra N, Vyas SP. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target. 2007 Dec;15(10):701-713.
82. Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y, Nagai T. Pharmaceutical and immunological evaluation of a single dose hepatitis B vaccine using PLGA microspheres. J Control Release. 2006;112: 35-42.
83. Bivas-Benita M, Lin MY, Bal SM, van Meijgaarden KE, Kees L.M.C. Franken, Friggen AH, Junginger HE, Borchard G, Klein MR, Ottenhoff TMH. Pulmonary delivery of DNA encoding mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine. 2009;27(30):4010-4017.
84. Yang S, Yuan W, Jin T. Formulating protein therapeutics into particulate forms. Expert Opin Drug Deliv. 2009;6(10):1123-1133.
85. Bala I, Hariharan H, Ravi Kumar MNV. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21(5):387-422.
86. Kumar N, Langer RS, Domb AJ. Polyanhydrides: an overview. Adv Drug Deliv Rev. 2002 Oct 16;54(7):889-910.
87. Lee W, Chu I. Preparation and degradation behavior of polyanhydrides nanoparticles. J Biomed Mater Res B Appl Biomater. 2008 Jan;84(1):138-146.
88. Gopferich A, Tessmar J. Polyanhydride degradation and erosion. Adv Drug Deliv Rev. 2002;54: 911-931.
89. Katti DS, Lakshmi S, Langer R, Laurencin CT. Toxicity, biodegradation and elimination of polyanhydrides. Adv Drug Deliv Rev 2002;54:933-961.
90. Wu C, Fu J, Zhao Y. Novel nanoparticles formed viaself-assembly of poly(ethylene glycol-b-sebacic anhydride) and their degradation in water. Macromolecules. 2000;33:9040-9043.
91. Masters DB, Berde CB, Dutta S, Turek T, Langer R. Sustained local anesthetic release from bioerodible polymer matrices:a potential method for prolonged regional anesthesia. Pharm Res. 1993;10(10):1527-1532.
92. Agüeros M, Ruiz-Gatón L, Vauthier C, Bouchemal K, Espuelas S, Ponchel G, Irache JM. Combined hydroxypropyl-beta-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci. 2009 Nov 5;38(4):405-413.
93. Irache JM, Salman HH, Gomez S, Espuelas S, Gamazo C. Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination. Front Biosci (Schol Ed). 2010 Jun 1;2:876-890.
94. Jain JP, Chitkara D, Kumar N. Polyanhydrides as localized drug delivery carrier: an update. Expert Opin Drug Deliv. 2008;5(8):889-907.
95. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):1-18.
96. Lassalle V, Ferreira MJ. PLA nano- and microparticles for drug delivery: an overview of the methods of preparation. Macromol Biosci. 2007 Jun 7;7(6):767-783.
97. Allemann E, Leroux J, Gurny R, Doelker E. In vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res. 1993 Dec;10(12):1732-1737.
98. Fishbein I, Chorny M, Banai S, Levitzki A, Danenberg HD, Gao J, Chen X, Moerman E, Gati I, Goldwasser V, Golomb G. Formulation and delivery mode affect disposition and activity of tyrphostinloaded nanoparticles in the rat carotid model. Arterioscler Thromb Vasc Biol. 2001;21(9):1434-1439.
99. Matsumoto J, Nakada Y, Sakurai K, Nakamura T, Takahashi Y. Preparation of nanoparticles consisted of poly(L-lactide)-poly(ethylene glycol)-poly(L-lactide) and their evaluation in vitro. Int J Pharm. 1999;185(1):93-101.
100. Xing J, Zhang D, Tan T. Studies on the oridonin-loaded poly(D,L-lactic acid) nanoparticles in vitro and in vivo. Int J Biol Macromol. 2007;40(2):153-158.
101. Lee SH, Zhang Z, Feng SS. Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials. 2007;28(11):2041-2050.
102. Zou W, Liu C, Chen Z, Zhang N. Preparation and characterization of cationic PLA-PEG nanoparticles for delivery of plasmid DNA. Nanoscale Res Lett. 2009;4(9):982-992.
103. Park YM, Shin BA, Oh IJ. Poly(L-lactic acid)/polyethylenimine nanoparticles as plasmid DNA carriers. Arch Pharm Res. 2008;31(1):96-102.
104. Wang J, Feng SS, Wang S, Chen ZY. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm. 2010 Nov 15;400(1-2):194-200.
105. Vila A, Sanchez A, Evora C, Soriano I, Vila Jato JL, Alonso MJ. PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med. 2004;17(2):174-185.
106. Chen J, Tian B, Yin X, Zhang Y, Hu Z, Liu M, Pan Y, Zhao J, Li H, Hou C, Wang J, Zhang Y. Preparation, characterization and transfection efficiency of cationic PEGylated PLA nanoparticles as gene delivery systems. J Biotechnol 2007;130:107-113.
107. Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G, Lee VHL, Fresta M. Influence of preparation conditions on acyclovir-loaded poly-D,L-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003;20:584-590.
108. Harmia T, Tuomi A, Kristoffersson E. Manufacture of polyalkylcyanoacrylate nanoparticles with pilocarpine and timolol by micelle polymerization:factors influencing particle formation. J Microencapsul. 1989;6:87-93.
109. Li VH, Wood RW, Kreuter J, Harmia T, Robinson JR. Ocular drug delivery of progesterone using nanoparticles. J Microencapsul. 1986;3:213-218.
110. Phillips, MI, Zhang Y. Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use. U.S. Patent 6489307; 2000.
111. Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmcol. 1996;48:1147-1152
112. Pinto-Alphandary H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles:research and applications. Int J Antimicrob Agents. 2000;13:155-168.
113. Mitra S, Maitra A. Nanoparticulate carriers in drug delivery and targeting. Proc Indian Natn Sci Acad (PINSA). 2002;68(4):349-360
114. Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Deliv. 2006;3(1):139-162.
115. Batrakova EV, Li S, Brynskikh AM, Sharma AK, Li Y, Boska M, Gong N, Mosley RL, Alakhov VY, Gendelman HE, Kabanov AV. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers, J Control Release. 2010;143(3):290-301.
116. Luxenhofer R, Schulz A, Roques C, Li S, Bronich TK, Batrakova EV, Jordan R, Kabanov AV. Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs. Biomaterials. 2010;31:4972-4979.
117. Price TO, Farr SA, Yi X, Vinogradov S, Batrakova EV, Banks WA, Kabanov AV. Transport across the blood-brain barrier of pluronic leptin. J Pharmacol Exp Ther. 2010;333(1):253-263.
118. Wang Y, Han P, Xu H, Wang Z, Zhang X, Kabanov AV. Photocontrolled self-assembly and disassembly of block ionomer complex vesicles: a facile approach toward supramolecular polymer nanocontainers. Langmuir. 2010;26(2):709-715.
119. Oha KT, Ohb YT, Ohc NM, Kimd K, Leee DH, Leec ES. A smart flower-like polymeric micelle for pH-triggered anticancer drug release. Int J Pharm. 2009;375:163-169.
120. Choi K, Bang J, Kimc P, Kimd C, Songe C. Amphotericin B-incorporated polymeric micelles composed of poly (d,l-lactide-co-glycolide)/dextran graft copolymer. Int J Pharm. 2008;355:224-230.
121. Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Rowen E, Yu J, Kerr RO. Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest. 2010;28:186-194.
122. Jeong Y, Nah J, Lee H, Kim S, Cho C. Adriamycin release from flower-type polymeric micelle based on star-block copolymer composed of poly(g-benzyl L-glutamate) as the hydrophobic part and poly(ethylene oxide) as the hydrophilic part. Int J Pharm. 1999;188:49-58.
123. Richter A, Olbrich C, Krause M, Kissel T. Solubilization of Sagopilone, a poorly water-soluble anticancer drug, using polymeric micelles for parenteral delivery. Int J Pharm. 2010;389:244-253.
124. Li X, Huang Y, Chen X, Zhou Y, Zhang Y, Li P, Liu Y, Sun Y, Zhao J, Wang F. Self-assembly and characterization of Pluronic P105 micelles for liver-targeted delivery of silybin. J Drug Target. 2009 Dec;17(10):739-750.
125. Kim JK, Garripelli VK, Jeong UH, Park JS, Repka MA, Jo S. Novel pH-sensitive polyacetal-based block copolymers for controlled drug delivery. Int J Pharm. 2010 Nov 30;401(1-2):79-86.
126. Gaucher G, Satturwar P, Jones M, Furtos A, Leroux J. Polymeric micelles for oral drug delivery. Eur J Pharm Biopharm. 2010 Oct;76(2):147-158.
127. Mathot F, Beijsterveldt L, Preat V, Brewster M, Arien A. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J Control Release. 2006;111:47-55.
128. Ranger M, Jean-CL. Water-soluble stabilized self-assembled polyelectrolytes. U.S. Patent 7510731; 2009.
129. Seo MH, Kim BO, Choi IJ, Shim MS. Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery. U.S. Patent 7311901; 2007.
130. Husseini GA, Pitt WG. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev. 2008 Jun 30;60(10):1137-1152.
131. Kakizawa Y, Kataoka K. Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev. 2002 Feb 21;54(2):203-222.
132. Kim SY, Shin IG, Lee YA, Cho CS, Sung YK. Methoxy poly(ethylene glycol) and e -caprolactone amphiphilic block copolymeric micelle containing indomethacin. II. Micelle formation and drug release behaviours. J Control Release. 1998;51:13-22.
133. Hendradi E, Obata Y, Isowa K, Nagai T, Takayama K. Effect of mixed micelle formulations including terpenes on the transdermal delivery of diclofenac. Biol Pharm Bull. 2003;26:1739-1743.
134. Discher DE, Discher BM, Won YY, Lee JC-M, Bates FS, Hammer DA. Polymersomes and related encapsulating membranes. U.S. Patent 6835394; 2004.
135. Discher BM, Won Y, Ege DS, Lee JC, Bates FS, Discher DE, Hammer DA. Polymersomes: tough vesicles made from diblock copolymers. Science. 1999;284:1143-1146.
136. Najafia F, Sarbolouki MN. Biodegradable micelles/polymersomes from fumaric/sebacic acids and poly(ethylene glycol). Biomaterials. 2003;24:1175-1182.
137. Zhou W, Feijen J. Biodegradable polymersomes for controlled drug release. J Control Release. 2008;132:19-36.
138. Meng FH, Engbers GHM, Feijen J. Biodegradable polymersomes as a basis for artificial cells:encapsulation, release and targeting. J Control Release 2005;101:187-198.
139. Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C, Gao X, Jiang X, Zhu C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release. 2008;128:120-127.
140. Levine DH, Ghoroghchian P, Freudenberg J, Zhang G, Therien MJ, Greene MI, Hammer DA, Murali R. Polymersomes: a new multi-functional tool for cancer diagnosis and therapy. Methods. 2008;46:25-32.
141. Upadhyay KK, Bhatt AN, Mishra AK, Dwarakanath BS, Jain S, Schatz C, Le Meins J, Farooque A, Chandraiah G, Jain AK, Misra A, Lecommandoux S. The intracellular drug delivery and anti-tumor activity of doxorubicin loaded poly (g-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials. 2010;31:2882-2892.
142. Rastogi R, Anand S, Koul V. Flexible polymerosomes--an alternative vehicle for topical delivery. Colloids Surf B Biointerfaces. 2009 Aug 1;72(1):161-166.
143. Discher DE, Discher BM, Won YY, Lee JC-M, Bates FS, Hammer DA. Polymersomes and related encapsulating membranes. U.S. Patent Application 0181939; 2008.
144. Discher DE, Discher BM, Won YY, Lee JC-M, Bates FS, Hammer DA (Trustees of the University of Pennsylvania, Philadelphia, PA; Regents of the University of Minnesota, Minneapolis, MN, assignee) Polymersomes and related encapsulating membranes. U.S. Patent 7217427; 2007.
145. Reddy LH, Murthy RSR. Etoposide-loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release, and stability evaluation. AAPS PharmSciTech. 2005;6:158-166.
146. Hou D, Xie C, Huang K, Zhu C. The production and characterization of solid lipid nanoparticles. Biomaterials. 2003;24:1781-1785.
147. Utreja S, Jain NK. Solid lipid nanoparticles: advances in controlled and novel drug delivery. New Delhi, India: CBS Publishers; 2001. p. 408-425.
148. Hu F, Wu M, Yuan H, Zhanq HH. A novel preparation of solid lipid nanoparticles with cyclosporine A for prolonged drug release. Pharmazie. 2004;59:683-685.
149. Muller RH, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177.
150. Mehnert W, Mader K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Del Rev. 2001;47:165-196.
151. Vyas SP, Khar RK. Nanoparticles, targeted and controlled delivery: novel carrier systems. 1st ed. New Delhi, India: CBS Publishers; 2002. p. 331-384.
152. Pople V, Singh K. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS Pharm Sci Tech. 2006;7(4):1-7.
153. Jenning V, Gysler A, Schafer-Korting M, Gohla S. Vitamin A loaded solid lipid nanoparticles for topical use: Occlusive properties and drug penetration into porcine skin. Eur J Pharm Biopharm. 2000;49:211-218.
154. Wissing S, Maeder K, Rogaschewski S, Muller RH. Solid lipid nanoparticles (SLN)--a novel carrier for UV-blockers. Pharmazie. 2001;56:783-786.
155. De Vringer T. Topical preparation containing suspension of solid lipid particles. E.U. Patent EP0786251; 2003.
156. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid anoparticles after oral administration. Pharm Res. 1999;16:751-757.
157. Demirel M, Yazan Y, Muller H, Kilic F, Bozan B. Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul. 2001;18:359-371.
158. Sawant KK, Varia J, Dodiya S. Cyclosporin A loaded SLN: optimization of formulation, process variables and characterization. Curr Drug Deliv. 2008 Jan;5(1):64-69.
159. Serpev L, Catalano MG, Gasco MR, Cavalli R. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm. 2004;58: 673-680.
160. Sawant KK, Dodiya SS. Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul. 2008;2(2):120-135.
161. Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278:71-77.
162. Borgia SL, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, Roder B, Kramer KD, Schafer-Korting M. Lipid nanoparticles for skin penetration enhancement--orrelation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release. 2005;110:151-163.
163. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm. 2008;346:124-132.
164. Yuan H, Wang L, Du Y, You J, Hu F, Zeng S. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification. Colloids Surf B Biointerfaces. 2007 Nov 15;60(2):174-179.
165. Joshi MD, Muller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71(2):161-172.
166. Puri A, Loomis K, Smith B, Lee J, Yavlovich A, Heldman E, Blumenthal R. Lipid-based nanoparticles as pharmaceutical drug carriers:from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-580.
167. Tomalia DA. Birth of a new macromolecular architecture:dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog Polym Sci. 2005;30:294-324.
168. Duncan R, Izzo L. Dendrimer biocompatibility and toxicity. Adv Drug Del Rev. 2005;57:2215-2237.
169. Tomalia D, Frechet JMJ. Discovery of dendrimers and dendritic polymers: a brief historical perspective. Journal of Polymer Science Part A: Polymer Chemistry. 2002;40:2719-2728.
170. Sonke S, Tomalia DA. Dendrimers in biomedical applications--reflections on the field. Adv Drug Del Rev. 2005;57:2106-2129.
171. Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochim Pol. 2001;48(1):199-208.
172. Nanjwade BK, Bechra HM, Derkar GK, Manvi FV, Nanjwade VK. Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci. 2009 Oct 8;38(3):185-196.
173. Beezer AE, King ASH, Martin IK, Mitchel JC, Twyman LJ, Wain CF. Dendrimers as potential drug carriers;encapsulation of acidic hydrophobes within water soluble PAMAM derivatives. Tetrahedran. 2003;53:3873-3880.
174. Yang W, Cheng Y, Xu T, Wang X, Wen LP, Targeting cancer cells with biotinedendrimer conjugates. Eur J Med Chem. 2009;44:862-868.
175. Morgan MT, Nakanishi Y, Kroll DJ, Griset AP, Carnahan MA, Wathier M, Oberlies NH, Manikumar G, Wani MC, Grinstaff MW. Dendrimer-encapsulated camptothecins:increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res 2006;66(24):11913-11921.
176. Landers JJ, Cao Z, Lee I. Prevention of influenza pneumonitis by sialic acid-conjugated dendritic polymers. J Infect Dis. 2002;186:1222-1230.
177. Khopade AJ, Caruso F, Tripathi P, Nagaich S, Jain NK. Effect of dendrimer on entrapment and release of bioactive from liposomes. Int J Pharm. 2002;232:157-162.
178. Kurtoglua YE, Manoj BK. Mishra, Kannan SC, Kannana RM. Drug release characteristics of pamam dendrimer-drug conjugates with different linkers. Int J Pharm. 2010;384:189-194.
179. Boas U, Christensen JB, Heegaard PMH. Properties of dendrimers in biological systems. In: Boas U, Christensen JB, Heegaard PMH, editors. Dendrimers in medicine and biotechnology: new molecular tools. Cambridge, UK: Royal Society of Chemistry; 2006. p. 34.
180. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans. 2007 Feb;35(Pt 1):61-67.
181. Yang H, Lopina ST. Penicillin V-conjugated PEG-PAMAM star polymers. J Biomater Sci Polym Ed. 2003;14(10):1043-1056.
182. Tack F, Bakker A, Maes S, Dekeyser N, Bruining M, Elissen-Roman C, Janicot M, Brewster M, Janssen HM, De Waal BF, Fransen PM, Lou X, Meijer EW. Modified poly (propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J Drug Target. 2006 Feb;14(2):69-86.
183. Guillaudeu SJ, Fox ME, Haidar YM, Dy EE, Szoka FC, Frechet JM. PEGylated dendrimers with core functionality for biological applications. Bioconjug Chem. 2008;19(2):461-469.
184. Baker JR, Patri K, Kukowska-Latallo J. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev. 2005;57:2203-2214.
185. Chauhan AS, Sridevi S, Chalasani KB, Jain AK, Jain SK, Jain NK, Diwan PV. Dendrimer-mediated transdermal delivery:enhanced bioavailability of indomethacin, J Control Release. 2003;90:335-343.
186. Cheng Y, Man N, Xu T, Fu R, Wang X, Wang X, Wen L. Transdermal delivery of nonsteroidal antiinflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J Pharm Sci. 2007;96: 595-602.
187. Vandamme TF, Brobeck L. Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;102:23-38.
188. Spataro G, Malecaze F, Turrin C, Soler V, Duhayon C, Elena P, Majoral J, Caminade A. Designing dendrimers for ocular drug delivery. Eur J Med Chem. 2010 Jan;45(1):326-334.
189. Yao W, Sun K, Mu H, Liang N, Liu Y, Yao C, Liang R, Wang A. Preparation and characterization of puerarin-dendrimer complexes as an ocular drug delivery system. Drug Dev Ind Pharm. 2010 Sep;36(9):1027-1035.
190. Bai S, Thomas C, Ahsan F. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low molecular weight heparin. J Pharm Sci. 2007;96:2090-2106.
191. Tomalia DA, Hall MJ. Star/Comb branched polyamide. U.S. Patent 4599400; 1986.
192. Eguchi M, Da YZ, Ogawa Y, Okada T, Yumoto N, Kodaka M. Effects of conditions for preparing nanoparticles composed of aminoethylcarbamoyl-β-cyclodextrin and ethylene glycol diglycidyl ether on trap efficiency of a guest molecule. Int J Pharm. 2006;311:215-222.
193. Fernandez A, Jose M. Nanoparticles comprising chitosan and cyclodextrin. U.S. Patent Application 0220030; 2008.
194. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS Pharm. Sci.Tech. 2005;6:329-357.
195. Memisoglu-Bilensoy E, Sen M, Hincal AA. Effect of drug physicochemical properties on in vitro characteristics of amphiphilic cyclodextrin nanospheres and nanocapsules. J Microencapsul. 2006;23(1):59-68.
196. Hwang J, Rodgers K, Oliver JC, Schluep T. α-ethylprednisolone conjugated cyclodextrin polymerbased nanoparticles for rheumatoid arthritis therapy. Int J Nanomedicine. 2008;3:359-371.
197. Krauland AH, Alonso MJ. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int J Pharm. 2007;340:134-142.
198. Silveira M, Ponchel G, Puisieux F, Duchene D. Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs. Pharm Res. 1998;15: 1051-1055.
199. Duchene D, Ponchel G, Wouessidjewe D. Cyclodextrins in targeting application to nanoparticles. Adv Drug Deliv Rev. 1999;36:29-40.
200. Boudad H, Legrand P, Lebas G, Cheron M, Duchene D, Ponchel G. Combined hydroxypropylbeta-cyclodextrin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int J Pharm. 2001;218:113-124.
201. Radwan MA. Preparation and in vivo evaluation of parenteral metoclopramide-loaded poly (alkylcyanoacrylate) nanospheres in rats. J. Microencapsul. 2001;18:467-477.
202. Cavalli R, Peira E, Caputo O, Gasco MR. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with betacyclodextrins. Int J Pharm. 1999;182:59-69.
203. Monza Da Silveira A, Ponchel G, Duchene D, Couvreur P, Puisieux F. Nanoparticles comprising poly(isobutylcyanoacrylate) and cyclodextrins. EP 1 056 477 B1. 2005 [Patent in French].
204. Helena D. Cyclodextrins and their complexes, chemistry, analytical methods, applications. Weinheim, Germany: Wiley-VCH; 2006. p. 436-438.
205. Roux M, Perly B, Djedaini-Pilard F. Self-assemblies of amphiphilic cyclodextrins. Eur Biophys J. 2007;36:861-867.
206. Memisoglu-Bilensoy E, Vural I, Renoir JM. Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles:in vitro characteriziation and cytotoxicity. J Control Release. 2005;104:489-496.
207. Memisoglu E, Bochot A, Ozalp M, Sen M, Duchene D. Direct formation of nanospheres from amphiphilic beta-cyclodextrin inclusion complexes. Pharm Res. 2003;20:117-125.
208. Geze A, Aous S, Baussanne I, Putaux JL, Defaye J, Wouessidjewe D. Influence of chemical structure of amphiphilic β-cyclodextrins on their ability to form stable nanoparticles. Int J Pharm. 2002;242:301-305.
209. Vural I, Memisoglu-Bilensoy E, Renoir JM. Transcription efficiency of tamoxifen citrate loaded β-cyclodextrin nanoparticles. J Drug Deliv Sci Technol. 2005:15(5):339-342.
210. Cirpanli Y, Bilensoy E, Dogan AL, Calis S. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery. Eur J Pharm Biopharm. 2009;73(1):82-89.
211. Bacon R. Growth, structure, and properties of graphite whiskers. J Appl Phys. 1960;31:284-290.
212. Chemistry Explained.com [home page on the Internet]. Fullerenes [cited 2010 Nov 13]. Available from: http://www.chemistryexplained.com/Fe-Ge/Fullerenes.html.
213. Tran PA, Zhang L, Webster TJ. Carbon nanofibers and carbon nanotubes in regenerative medicine. Adv Drug Deliv Rev. 2009 Oct 5;61(12):1097-1114.
214. Dai H. Carbon nanotubes: synthesis, integration, and properties. Acc Chem Res. 2002;35(12):1035-1044.
215. Rodriguez NM. A review of catalytically grown carbon nanofibers. J Mater Res. 1993;8(12):3233-3250.
216. Hilder TA, Hill JM. Carbon nanotubes as drug delivery nanocapsules. Current Applied Physics. 2008;8:258-261.
217. Zakharian TY, Seryshev A, Sitharaman B, Gilbert BE, Knight V, Wilson LJ. A fullerene-paclitaxel chemotherapeutic:synthesis, characterization, and study of biological activity in tissue culture. J Am Chem Soc. 2005;127:12508-12509.
218. Foley S, Crowley C, Smaihi M, Bonfils C, Erlanger BF, Seta P, Larroque C. Cellular localisation of a water-soluble fullerene derivative. Biochem Biophys Res Commun. 2002;294:116-119.
219. Chen Q, Wang Q, Liu YC, Wu T, Kang Y, Moore JD, Gubbins KE. Energetics investigation on encapsulation of protein/peptide drugs in carbon nanotubes. J Chem Phys. 2009;131(1):015101
220. Weng X, Wang M, Ge J, Yu S, Liu B, Zhong J, Kong J. Carbon nanotubes as a protein toxin transporter for selective HER2-positive breast cancer cell destruction. Mol Biosyst. 2009;10:1224-1231.
221. Inoue Y, Fujimoto H, Ogino T, Iwata H. Site-specific gene transfer with high efficiency onto a carbon nanotube-loaded electrode. J R Soc Interface. 2008 Aug 6;5(25):909-918.
222. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008;68 (16):6652-6660.
223. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv Drug Deliv Rev. 2006;58:1460-1470.
224. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008 Aug 15;68(16):6652-6660.
225. Schipper ML, Nakayama-Ratchford N, Davis CR, Kam NW, Chu P, Liu Z, Sun X, Dai H, Gambhir SS. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat Nanotechnol. 2008 Apr;3(4):216-221.
226. Sayes CM, Liang F, Hudson JL, Mendez J, Guo W, Beach JM, Moore VC, Doyle CD, West JL, Billups WE, Ausman KD, Colvin VL. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro. Toxicol Lett. 2006;161:135-142.
227. Yu JG, Huang KL, Liu SQ, Tang JC. Preparation and characterization of soluble methyl-b-cyclodextrin functionalized single-walled carbon nanotubes. Physica. 2008;40:689-692.
228. Shi D, Lian J, Wang W, Liu G, He P, Dong Z, Wang L, Ewing RC. Luminescent carbon nanotubes by surface functionalization. Adv. Mater. 2006;18:189-193.
229. Marchesan S, Da Ros T, Spalluto G, Balzarini J, Prato M. Anti-HIV properties of cationic fullerene derivatives. Bioorg Med Chem Lett. 2005;15:3615-3618.
230. Xiao L, Takada H, Maeda K, Haramoto M, Miwa N. Antioxidant effects of water-soluble fullerene derivatives against ultraviolet ray or peroxylipid through their action of scavenging the reactive oxygen species in human skin keratinocytes. Biomed Pharmacother. 2005;59:351-358.
231. Mashino T, Nishikawa D, Takahashi K. Antibacterial and antiproliferative activity of cationic fullerene derivatives. Bioorg Med Chem Lett. 2003;13:4395-4397.
232. Simon F, Peterlik H, Pfeiffer R, Bernardi J, Kuzmany H. Fullerene release from the inside of carbon nanotubes:A possible route toward drug delivery. Chem Phys Lett. 2007;445:288-292.
233. Lezzi EB, Cai T, Ge Z, Glass TE, Harich K, Gibson HW, Dorn HC. Synthesis and characterization of the first trimetallic nitride templated pyrrolidino endohedral metallofullerenes. Chem Commun (Camb). 2005;28:3594-3596.
234. James WH, Moncur C. Rheumatoid arthritis: status of drug therapies. Physical Therapy. 1995;75: 511-525.
235. Huaizhi Z, Yuantao N. China's ancient gold drug. Gold Bulletin 2001;34(1):24-29.
236. Edelman ER, Seifert P, Groothuis A, Morss A, Bornstein D, Rogers C. Gold-Coated NIR stents in porcine coronary arteries. Circulation. 2001;103;429-434.
237. Donaldson JA. Use of gold in dentistry part I. Gold Bulletin. 1980;13:117-124.
238. Donaldson JA. Use of gold in dentistry part II. Gold Bulletin. 1980;13:160-165.
239. Pricker SP. Medicinal uses of gold compound: past, present and future. Gold Bulletin. 1996;29(2): 53-60.
240. Tiekink ERT. Gold compounds in medicine: potential anti-tumour agents. Gold Bulletin. 2003;36: 117-124.
241. Krpetic Z, Porta F, Scari G. Selective entrance of gold nanoparticles into cancer cells. Gold Bulletin. 2006;39:66-68.
242. Fonteha P, Meyer D. Novel gold (I) phosphine compounds inhibit HIV-1 enzymes. Metallomics. 2009;1:427-433.
243. Ghosh P, Han G, De M, Kim CK, Rotello VM. Applications of gold nanoparticles in cancer Nanotechnology. Adv Drug Del Rev. 2008;60:1307-1315.
244. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Del Rev. 2008;60(11):1307-1315.
245. Akbarzadeh A, Zare D, Farhangi A, Mehrabi MZ, Norouzian D. Synthesis and characterization of gold nanoparticles by tryptophane. Am J Appl Sci. 2009;6(4):691-695.
246. Ashkarran AA, Zad AI, Mahdavi SM, Ahadian MM, Nezhad MRH. Rapid and efficient synthesis of colloidal gold nanoparticles by arc discharge method. Applied Physics A: Materials Science & Processing. 2009;96(2):423-428.
247. Dong S, Tang C, Zhou H, Zhao H. Synthesis of gold nanoparticles by the sunlight radiation using a seeding approach. Gold Bulletin 2004;37:3-4.
248. Khosroshahi ME, Nourbakhsh MS. Preparation and characterization of self assembled gold nanoparticles on amino functionalized SiO2 dielectric core. World Academy of Science, Engineering and Technology. 2010; 64:353-356.
249. Kimling J, Maier M, Okenve B, Kotaidis V, Ballot H, Plech A. Turkevich method for gold nanoparticle synthesis revisited. J Phys Chem B. 2006 Aug 17;110(32):15700-15707.
250. Abecassis B, Testard F, Kong Q, Francois B, Spalla O. Influence of monomer feeding on a fast gold nanoparticles synthesis:time-resolved XANES and SAXS experiments. Langmuir. 2010;26(17): 13847-13854.
251. Kharisov BI, Kharissova OV, Yacaman MJ, Ortiz M U. State of the art of the bi- and trimetallic nanoparticles on the basis of gold and iron. Recent Pat Nanotechnol. 2009;3(2):81-98.
252. Martin MN, Basham JI, Chando P, Eah SK. Charged gold nanoparticles in non-polar solvents:10-min synthesis and 2D self-assembly. Langmuir. 2010;26(10):7410-7417.
253. Chen PC, Mwakwari SC, Oyelere AK. Gold nanoparticles: from nanomedicine to nanosensing. Nanotechnology, Science and Applications. 2008;1:45-66.
254. Caruso F, Angelatos AS, Radt B. Light-responsive polyelectrolyte/gold nanoparticle microcapsules. J Phys Chem B. 2005;109:3071-3076.
255. Huang HC, Koria P, Parker SM, Selby L, Megeed Z, Rege K. Optically responsive gold nanorodpolypeptide assemblies. Langmuir. 2008;24(24):14139-14144.
256. Paasonen L, Sipila T, Subrizi A, Laurinmaki P, Butcher SJ, Rappolt M, Yaghmur A, Urtti A, Yliperttula M. Gold-embedded photosensitive liposomes for drug delivery:triggering mechanism and intracellular release. J Control Release. 2010;147(1):136-143.
257. Russell DA, Wieder ME, Hone DC, Cook MJ, Handsley MM, Gavrilovic J. Intracellular photodynamic therapy with photosensitizer-nanoparticle conjugates: cancer therapy using a 'Trojan horse'. Photochem Photobiol Sci. 2006;5:727-732.
258. Guan J, Li J, Guo Y, Yang W. Cooperative dual-stimuli-triggered aggregation of poly-L-histidinefunctionalized au nanoparticles. Langmuir. 2009;25(5):2679-2683.
259. Schneider GF, Subr V, Ulbrich K, Decher G. Multifunctional cytotoxic stealth nanoparticles. A model approach with potential for cancer therapy. Nano Lett. 2009;9(2):636-642.
260. Paciotti F, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin E, Tamarkin L. Colloidal Gold: A Novel nanoparticle vector for tumor directed drug delivery. Drug Delivery. 2004;11:169-183
261. Patra CR, Bhattacharya R, Mukherjee P. Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J Mater Chem. 2010;20(3):547-554.
262. Huang Y, Yu F, Park YS, Wang J, Shin MC, Chung HS, Yang VC. Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials. 2010 Dec;31(34):9086-9091.
263. Duncan B, Kim C, Rotello VM. Gold nanoparticle platforms as drug and biomacromolecule delivery systems. J Control Release. 2010 Jun 11. [Epub ahead of print]
264. World Gold Council [homepage on the Internet]. The gold bulletin [cited July 2010]. Available from: www.goldbulletin.org.
265. Kuroda K, Chuzo K. The preparation of alkyltrimethylammonium kanemite complexes and their conversion to microporous silica. Bull Chem. 1990;63:988-992.
266. Beck JS, Vartuli JC, Ruth WJ, Leonowicz ME, Kresge CT, Schimitt KD, Chu CT-W, Olsan DH, Shepard EW, McCullen SB, Higgins JB, Shlenker JL. A new family of mesoporous molecular sieves prepared with liquid crystals template. J Am Chem Soc. 1992;114:10834-10843.
267. Zhao D, Feng J, Huo Q, Melosh N, Fredrickson GH, Chmelka BF, Stucky GD. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science. 1998 Jan 23;279(5350):548-552.
268. Uglea V, Albu I, Vatajanu A, Croitoru M, Antoniu S, Panaitescu L, Ottenbrite RM. Drug delivery systems based on inorganic materials:I. Synthesis and characterization of a zeolite-cyclophosphamide system. J Biomater Sci Polym Ed. 1994;6:633-637.
269. Wang L, Wu L, Lu S, Chang L, Teng I, Yang C, Ho JA. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. ACS Nano 2010;4(8):4371-4379.
270. Son J, Reichel J, He B, Schuchman M, Lee SB. Magnetic nanotubes for magnetic-field-assisted bioseparation, biointeraction and drug delivery. J Am Chem Soc. 2005;127:7316-7317.
271. Radu DR, Lai CY, Jeftinija K, Rowe EW, Jeftinija S, Lin VSY, A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent J Am Chem Soc. 2004;126:13216.
272. Lin YS, Tsai CP, Huang HY, Kuo CT, Hung Y, Huang DM, Chen YC, Mou CY. Well-ordered mesoporous silica nanoparticles as cell markers. Chem Mater. 2005;17:4570.
273. Anglin EJ, Cheng L, Freeman WR, Sailor MJ. Porous silicon in drug delivery devices and materials. Adv Drug Del Rev. 2008;60:1266-1277.
274. Lu J, Liong M, Zink EI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small. 2007;3(8):1341-1346.
275. Slowing II, Vivero-Escoto JL, Wu CW, Lin VS-Y. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Del Rev. 2008;60:1278-1288.
276. Lai C, Trewyn BG, Jeftinija DM, Jeftinija K, Xu S, Jeftinija S, Lin VS. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc. 2003;125(15):4451-4459.
277. Zhao Y, Vivero-Escoto JL, Slowing I, Trewyn BG, Lin VS. Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery. Expert Opin Drug Deliv. 2010;7(9):1013-1029.
278. Iga AM, Robertson JH, Winslet MC, Seifalian AM. Clinical potential of quantum dots. J Biomed Biotechnol. 2007;2007(10):76087.
279. Dabbousi BO, Rodriguez-Viejo J, Mikulec FV, Heine JR, Mattoussi H, Ober R, Jensen KF, Bawendi MG. (CdSe) ZnS core-shell quantum dots: synthesis and characterization of a size series of highly luminescent nanocrystallites. J Phys Chem B. 1997;101:9463-9475.
280. Hezinger AFE, Temar J, Gopferich A. Polymer coating of quantum dots--a powerful tool toward diagnostics and sensorics. Eur J Pharm Biopharm. 2008;68:138-152.
281. Bawendi MG, Mikulec FV, Sundar VC. Biological applications of quantum dots. U.S. Patent 6306610 B1; 2001.
282. Shen MY, Goto T, Kurtz E, Zhu Z, Yao T. Photoluminescence properties of single CdSe quantum dots in ZnSe obtained by self-organized growth. J Phys Condens Matter. 1998;10:171.
283. Rzigalinski BA, Strobl JS. Cadmium-containing nanoparticles: perspectives on pharmacology and toxicology of quantum dots. Toxicol Appl Pharmacol. 2009 Aug 1;238(3):280-288.
284. Juzenas P, Chen W, Sun YP. Coelho MAN, Generalov R, Generalova N, Christensen IL. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv Drug Del Rev. 2008;60:1600-1614.
285. Smith AM, Duan H, Mohs AM, Shuming N. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Del Rev. 2008;60:1226-1240.
286. Xing Y, Rao J. Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. Cancer Biomark. 2008;4(6):307-319.
287. Manabe N, Hoshino A, Liang YQ, Goto T, Kato N, Yamamoto K. Quantum dot as a drug tracer in vivo. IEEE Trans Nanobioscience. 2006 Dec;5(4):263-267.
288. Derfus AM, Chen AA, Bhatia SN. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem. 2007 Sep-Oct;18(5):1391-1396.
289. Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007;7:3065-3070.
290. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22:969-976.
291. Ho YP, Chen HH, Leong KW, Wang TH. Evaluating the intracellular stability and unpacking of DNA nanocomplexes by quantum dots-FRET. J Control Release. 2006;116:83-89.
292. Sheng W, Kim S, Lee J, Kim S-W, Jensen K, Bawendi MG. In-situ encapsulation of quantum dots into polymer microspheres. Langmuir. 2006;22:3782-3790.
293. Guo G, Liu W, Liang J, Xu H, He Z, Yang X. Preparation and characterization of novel CdSe quantum dots modified with poly (D, L-lactide) nanoparticles. Mater Lett. 2006;60:2565-2568.
294. Qi L, Gao Z. Emerging application of quantum dots for drug delivery and therapy. Expert Opin Drug Deliv. 2008;5(3):263-267.
295. Teague C. Opinion: a misleading portrait of nanotechnology [cited July 2010]. Available from: http://www.aolnews.com/category/opinion/.
296. Hughes GA. Nanostructure-mediated drug delivery. Nanomedicine. 2005 Mar;1(1):22-30.
297. Bawa J. Nanoparticle-based therapeutics in humans: a survey. Nanotechnology Law & Business. 2008;5(2):135-155.
298. MarketResearch.com [homepage on the Internet]. Nanotechnology market [cited July 2010]. Available from: www.marketresearch.com.
299. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007 Mar;3(1):20-31.
300. Ochekpe NA, Olorunfemi PO, Ngwuluka NC. Nanotechnology and drug delivery part 2: nanostructures for drug delivery. Tropical Journal of Pharmaceutic Research. 2009;8(3):275-287.
301. National Nanotechnology Initiative [homepage on the Internet]. Applications and products: putting technology to use [cited July 2010]. Available from: http://www.nano.gov/html/facts/nanoapplicationsandproducts.html.
302. Ortho-McNeil-Janssen Pharmaceuticals [homepage on the Internet]. Important safety information for Invega® Sustenna® [cited July 2010]. Available from: http://www.janssen.com/products.html.
303. TM. http://www.com (Cited July 2010). Available from: http://biosantepharma.com/.
304. Gradishar WJ, Albumin-bound paclitaxel:a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041-1053.
305. ClinicalTrials.gov [homepage on the Internet]. Phase I & II trial of intravesicular abraxane for treatment- refractory bladder cancer [cited July 2010]. Available from: http://www.clinicaltrials.gov/NCT00583349.
306. ClinicalTrials.gov [homepage on the Internet]. Carboplatin and paclitaxel albumin-stabilized nanoparticle formulation in treating patients with advanced or metastatic solid tumors [cited July 2010]. Available from: http://www.clinicaltrials.gov/NCT00520000.
307. Chiechi LM. Estrasorb novavax. Drugs. 2004;7(9):860-864.
308. ClinicalTrials.gov [homepage on the Internet]. Clinical study of antibacterial nanoparticles incorporated in composite restorations [cited July 2010]. Available from: http://www.clinicaltrials.gov/NCT00299598.
309. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Del Rev. 2007;59(6):522-530.
310. Successful completion of VivaGel ® in Sexually Active Women [cited Feb 2011]. Available from: http://www.starpharma.com/data100312%20Successful%20completion%20of%20VivaGel%20study%20in%20sexually%20active%20women.pdf.
311. Abbot Laboratories. TriCor (fenofibrate) tablets [cited July 2010]. Available from: http://www.abbott.com/global/url/content/en_US/20.10.207:207/product/Product_Master_0209.htm.
312. Alpha RX, Zysolin ™ [cited July 2010]. Available from: http://www.alpharx.com/docs09/products.php?submenuid=products_menu&category=products/investorsmain.